The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one of its priority candidates to treat lupus through the LRxL-STAT Lupus Drug Repositioning Initiative. The selection of the drug was presented at the annual American College…
A new case study entitled “Acute kidney injury associated with minimal change disease in systemic lupus erythematosus: a case report” describes a rare case of a patient with Systemic lupus erythematosus and acute kidney injury associated with minimal change disease. The study was published in the Journal…
A clinical review entitled “Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature” was recently published in the journal Pediatric Rheumatology. Juvenile-onset systemic lupus erythematosus (JSLE) is a common systemic autoimmune connective tissue condition that affects children. Estimations of JSLE are of…
Biopharmaceutical company Anthera Pharmaceuticals, Inc. is hosting a symposium on Systemic Lupus Erythematosus (SLE) designed for shareholders and investors, which is taking place on Wednesday, January 14, at 3:30 pm at the Mystic Hotel in San Francisco, CA. Anther is focused on the development and commercialization of medical options for the treatment of…
The New York and Chicago based non-profit Lupus Research Institute (LRI) Coalition, along with lupus patients nationwide are hopeful that the year-end Congressional Fiscal 2015 Consolidated and Further Continuing Appropriations Act will authorize support for several lupus research and professional education programs after the organization’s year-log advocacy. An…
According to research recently published in the American Society for Microbiology’s journal Applied and Environmental Microbiology, Lactobacillus — a probiotic (beneficial bacteria) species commonly found in yogurt cultures — has been discovered to correlate in the gut of laboratory mouse models, with symptom mitigation in the autoimmune disorder systemic…